Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445399 in Moderate to Severe Hidradenitis Suppurativa
NCT07225569Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Dec 2025
- Primary completion
- Sep 2027
- Modality
- Nanobodies (VHH)
- Countries
- 15
01
Overview
A Phase 2 trial of SAR445399 in hidradenitis suppurativa (HS), sponsored by Sanofi. Started Dec 2025; status: recruiting.
02
Drugs
SAR445399
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07225569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225569.